IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Mauritius

Mauritius

Continent:	Africa
Capital:	Port Louis
Population:	1294104
Area (in sq km):	2040.0

Haemoglobinopathy-specific healthcare policy information for Mauritius

Healthcare policy		Comment/Info
Rare disease patient registry:	No	http://africa-rare.org/
Dedicated treatment centres:	Yes (National)
Patient associations:	Yes (National)

Prevalence and incidence of major haemoglobinopathies in Mauritius

Haemoglobinopathy		Reference
Prevalence of β-thalassaemia carriers:	3.85 % of the population	[PMID: 7717387]
Prevalence of sickle cell disease carriers:	1.42 % of the population	[PMID: 7717387]
Prevalence of Hb E carriers:	0.71 % of the population	[PMID: 7717387]

Global Burden of Disease data for Mauritius

Migration data for Mauritius

Mutation frequencies in Mauritius

Overview (most frequent mutations with their observed average values and range)

β-locus

IVS I-5 (G>C): 79.13 % (74 % – 83 %)	CD 26 GAG>AAG [Glu>Lys] (HbE): 10.4 %
-28 (A>C): 6.5 %	CD 8/9 (+G): 4.67 % (3.5 % – 6.5 %)

Detailed mutation frequencies

Entry ID	Locus	Region	Ethnic Group	Population Type	Sample Size	Study period (to)	Reference	Comments
21251	β-locus	Moka	Mauritian	Patients	46	2007	17994378	Frequencies are shown for beta-globin gene mutations. Study samples were acquired from the Sir Seewoosagur Ramgoolam (SSR) Centre for Medical Studies and Research, Moka.
21252	β-locus	Country-wide	Indo-Mauritian	Patients	85	2000	10602161	Frequencies are shown for beta-globin gene mutations. Study samples were acquired from the four major hospitals of the country.
21253	β-locus	Country-wide	Mauritian	Carriers and Patients	55	2001	11791873	Frequencies are shown for beta-globin gene mutations. The majority of samples studied were patients.

Organisations in Mauritius

Organisations in Mauritius are currently not available

Microattributions

No microattibutions were provided for Mauritius. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: